An open-label study of pegylated liposomal doxorubicin, vincristine and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients in Chinese population

被引：0
|
作者：
Shen, Yang [1 ]
Shen, Zhixiang [1 ]
Jiang, Bin [2 ]
Hou, Jian [3 ]
Zhan, Rong [4 ]
Qiu, Lugui [5 ]
Wu, Yongji [6 ]
Jin, Jie [7 ]
Li, Juan [8 ]
Meng, Fanyi [9 ]
Zou, Ping [10 ]
Liu, Ting [11 ]
Li, Jianyong [12 ]
Wang, Chun [13 ]
Wu, Depai [14 ]
Ma, Jun [15 ]
机构：
[1] Shanghai Ruijin Hosp, Dept Hematol, Shanghai 100871, Peoples R China
[2] Beijing Univ, Renmin Hosp, Dept Hematol, Beijing, Peoples R China
[3] Changzheng Hosp, Dept Hematol, Shanghai, Peoples R China
[4] Fujian Med Univ, Union Hosp, Dept Hematol, Fuzhou, Peoples R China
[5] CAMS, Inst Hematol, Dept Hematol, Tianjin 100871, Peoples R China
[6] Beijing Union Med Coll Hosp, Dept Hematol, Beijing 310027, Peoples R China
[7] Hosp Zhejiang Univ 1st, Dept Hematol, Hangzhou, Peoples R China
[8] Hosp Zhongshan Univ 1st, Dept Hematol, Guangzhou, Guangdong, Peoples R China
[9] Nanfang Hosp, Dept Hematol, Guangzhou, Guangdong, Peoples R China
[10] Wu Han Union Hosp, Dept Hematol, Wuhan, Peoples R China
[11] Huaxi Hosp, Dept Hematol, Chengdu, Peoples R China
[12] Jiangsu Prov People Hosp, Dept Hematol, Nanjing, Peoples R China
[13] Shanghai 1st People Hosp, Dept Hematol, Shanghai, Peoples R China
[14] 1st Hosp Suzhou Med Univ, Dept Hematol, Suzhou, Peoples R China
[15] Haerbin Hematol Inst, Haerbin, Peoples R China
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
10.1182/blood.V110.11.4816.4816
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4816
引用
收藏
页码：278B / 278B
页数：1
相关论文
共 50 条
  • [1] An Open-Label Study of Pegylated Liposomal Doxorubicin,Vincristine, and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in the Chinese Population
    Yang ShenZhixiang ShenBin JiangJian HouRong ZhanLugui QiuDaobin ZhouJie JinJuan LiFanyi MengPing ZouTing LiuJianyong LiChun WangDepei WuJun Ma 1 Department of Hematology
    Cancer Biology & Medicine, 2009, 6 (06) : 394 - 400
  • [2] A phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients
    Hussein, MA
    Wood, L
    Hsi, E
    Srkalovic, G
    Karam, M
    Elson, P
    Bukowski, RM
    CANCER, 2002, 95 (10) : 2160 - 2168
  • [3] Modifications to therapy for multiple myeloma: Pegylated liposomal doxorubicin in combination with vincristine, reduced-dose dexamethasone, and thalidomide
    Hussein, MA
    ONCOLOGIST, 2003, 8 : 39 - 45
  • [4] Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma
    Hussein, M
    CLINICAL LYMPHOMA, 2003, 4 : S18 - S22
  • [5] Clinical benefits and economic analysis of pegylated liposomal doxorubicin/vincristine/dexamethasone versus doxorubicin/vincristine/dexamethasone in patients with newly diagnosed multiple myeloma
    Porter, Christopher A.
    Rifkin, Robert M.
    CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S150 - S155
  • [6] An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma
    Nishihori, Taiga
    Baz, Rachid
    Shain, Kenneth
    Kim, Jongphil
    Ochoa-Bayona, Jose L.
    Yue, Binglin
    Sullivan, Daniel
    Dalton, William
    Alsina, Melissa
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, 95 (05) : 426 - 435
  • [7] Pegylated liposomal doxorubicin (PLD), vincristine and reduced-dose dexamethasone (DVd) in the treatment of a predominantly African American population with multiple myeloma.
    Jajeh, A
    Catchatourian, R
    Osafo, D
    Tamkus, D
    Zalzaleh, G
    Bamrolia, A
    BLOOD, 2005, 106 (11) : 723A - 724A
  • [8] Pegylated liposomal doxorubicin (PLD), vincristine and reduced-dose dexamethasone (DVd) in the treatment of predominantly African American population with multiple myeloma.
    Bamrolia, Anshul
    Jajeh, Ahmad
    Catchatourian, R.
    Osafo, David
    Tamkus, Deimante
    Sharma, Neelesh
    Zalzaleh, Ghassan
    Nathan, Sunita
    Menini, Perry
    BLOOD, 2006, 108 (11) : 365B - 365B
  • [9] Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma
    Jakubowiak, Andrzej J.
    Kendall, Tara
    Al-Zoubi, Ammar
    Khaled, Yasser
    Mineishi, Shin
    Ahmed, Asra
    Campagnaro, Erica
    Brozo, Christine
    Braun, Thomas
    Talpaz, Moshe
    Kaminski, Mark S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (30) : 5015 - 5022
  • [10] Pegylated liposomal doxorubicin (Doxil®), dexamethasone and low dose thalidomide (DDt) as therapy for newly diagnosed multiple myeloma.
    Deauna-Limayo, D
    Aljitawi, OS
    Mayo, M
    Bodensteiner, DC
    Ganguly, S
    Skikne, BS
    Suman, K
    BLOOD, 2005, 106 (11) : 374B - 374B
12345